Therapeutics (19) Apply Therapeutics filter
Research Tools (3) Apply Research Tools filter
Diagnostics (2) Apply Diagnostics filter
Vaccines (1) Apply Vaccines filter
Pre-clinical (in vivo) (14) Apply Pre-clinical (in vivo) filter
Prototype (5) Apply Prototype filter
Discovery (Lead Identification) (4) Apply Discovery (Lead Identification) filter
Basic (Target Identification) (2) Apply Basic (Target Identification) filter
Cancer/Neoplasm (27) Apply Cancer/Neoplasm filter
Infectious Diseases (27) Apply Infectious Diseases filter
Immune System and Inflammation (11) Apply Immune System and Inflammation filter
Central Nervous System (2) Apply Central Nervous System filter
Metabolic Disease (2) Apply Metabolic Disease filter
NCI - National Cancer Institute (27) Apply NCI - National Cancer Institute filter
Showing 1-20 of 27 results found
Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging
Researchers at the University of California, Irvine (UCI) and NCI seek licensing for a new family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.
Automated Digital Pathology Device for High-Throughput Demand
The National Cancer Institute (NCI) seeks licensees for an automated digital pathology device which integrates tissue sectioning, staining, and image acquisition. The device is compatible with high-throughput data analyses.
T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a method to identify T cells with preferred phenotypes for increased response from adoptive immunotherapy.
Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells
Pluripotent stem cells are a promising source of T cells for a variety of clinical applications. However, current in vitro methods of T cell differentiation result in the generation of cells with aberrant phenotypes. Researchers at the National Cancer Institute (NCI) have now developed methodology for generating induced pluripotent stem cell thymic emigrants (iTE). Antigen-specific CD8αβ+ iTEs exhibited functional properties in vitro that were almost indistinguishable from natural naïve CD8αβ+ T cells, including vigorous expansion and robust anti-tumor activity. iTEs recapitulated many of the transcriptional programs of naïve T cells in vivo and revealed a striking capacity for engraftment, memory formation, and efficient tumor destruction. The NCI seeks licensing and/or co-development research collaborations for this invention.
Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics
Scientists at the National Cancer Institute (NCI) have developed a novel delivery platform in which the scaffold of an anionic hydrogel (AcVES3) can be attenuated to deliver therapeutic small molecules, peptides, proteins, nanoparticles, or whole cells. The NCI seeks collaborators and licensees for the development of this technology in various clinical and laboratory applications.
Design and Biological Activity of Novel Stealth Polymeric Lipid Nanoparticles for Enhanced Delivery of Hydrophobic Photodynamic Therapy Drugs
Scientists at the National Cancer Institute (NCI) developed a novel stealth lipid-based nanoparticle formulation comprising phospholipid, DC8,9PC and a polyethylene glycol-ated (PEGylated) lipid – such as DSPE-PEG2000 – that efficiently package a high amounts of hydrophobic photodynamic drug (PDT) – such as HPPH – in stable vesicles. This HPPH-loaded liposome system demonstrates higher serum stability and ambient temperature stability upon storage. It exhibits increased tumor accumulation and improved animal survival in mice tumor models compared to the formulation in current clinical trials. The NCI seeks co-development partners and/or corporate licensees for the application of the technology as an anti-cancer therapeutic.
Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy
Researchers at the National Cancer Institute (NCI) developed a multiplex assay to determine the efficacy of apoptosis-related drugs targeting the Bcl2 family of proteins or aid in the selection of cancer patients likely to respond. The NCI seeks partners for co-development or licensees for commercialization of novel immunoassays for determining or predicting patient response to cancer therapy.
Efficient Cell-Free Production of Papillomavirus Gene Transfer Vectors
Researchers at the National Cancer Institute (NCI) developed cell free methods for efficiently producing high titer, papillomavirus virus-based gene transfer vectors. These vectors can potentially be used for vaccines and/or cancer therapeutic applications. NCI seeks licensing and/or co-development research collaborations for further development of these vectors.
New Insect Sf9-ET Cell Line for Determining Baculovirus Titers
The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.
Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus
The National Cancer Institute (NCI) seeks licensing of Bac-2-the-Future, an improved system for the production of recombinant baculovirus.
Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies
Researchers at the National Cancer Institute (NCI) seek research & co-development and/or licensees for a novel, ex vivo method by which stem cell-like memory T cells (Tscm) can be generated by stimulating naïve T cells in the presence of inhibitors of GSK-3beta, which are capable of activating the Wnt pathway. These Tscm cells, generated using GSK-3beta inhibitors, display enhanced survival and proliferation upon transfer, have multipotent capacity to generate all memory and effector T cell subsets, and show increased anti-tumor activity in a humanized mouse tumor model.
Renal Selective Unsaturated Englerin Analogues
Researchers at the National Cancer Institute (NCI) have developed a number of analogs of the natural product englerin A, an inhibitor of renal cancer cell growth. Englerin A is thought to exert its anticancer effects by activating protein kinase C (PKC) theta, and exert cytotoxic effects through activation of transient receptor potential cation (TRPC) channels. The invention englerin analogues provide promising treatment strategies for various cancers, diabetes, and HIV, and other diseases associated with the PKC theta and/or TRPC ion channel proteins. Researchers at the NCI seek licensing and/or co-development research collaborations for englerin A analogue compounds.
Polymeric Delivery Platform for Therapeutics
The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for a polymeric drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform delivers various immunomodulatory therapeutic cargo including small molecule drugs, therapeutic peptides, and vaccines, to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations.
Micro-Dose Calibrator for Pre-clinical Radiotracer Assays
Pre-clinical radiotracer biomedical research involves the use of compounds labeled with radioisotopes, including radio-ligand bio-distribution studies, cell binding studies, immune cell labeling techniques, and α-based therapies. Before this Micro-Dose Calibrator, measurement of pre-clinical level dosage for small animal studies was inaccurate and unreliable. This dose calibrator is a prototype ready for customer testing and scale-up. It is designed to accurately measure radioactive doses in the range of 50 nCi (1.8 kBq) to 100 µCi (3.7 MBq) with 99% precision. The NCI seeks co-development or licensing to commercialize it. Alternative uses will be considered.
Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles
Researchers at the National Cancer Institute (NCI) have developed nucleic-acid-based nanoparticle that can be adapted for RNA interference (RNAi), molecular imaging, or a combination thereof. The invention nanoparticles can be used as therapeutics in the treatment of cancer, whichthe NCI seeks parties to license or co-develop.
Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases
Researchers at the NCI have developed a method of improving the immune response in cancer immunotherapy by exploiting in the role of the Linker Adapted for T-Cell Signaling (LAT) molecule. The LAT molecular can enhance signaling through TCRs, thus, improving a patient's own immune response to cancer or infectious diseases.
Nanoparticles for the targeted treatment of infected cells
The National Cancer Institute seeks parties interested in collaborative research to license or co-develop and commercialize therapeutic RNA/DNA nanoparticles.
Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles
Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute's Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.